An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

2013604 citationsJournal Articlehybrid Open Access

Authors

The ALS Association, Muscular Dystrophy Association, Isis Pharmaceuticals.

Good health and well-being

Published in: The Lancet Neurology

Volume 12, Issue 5, pp. 435-442

Field-Weighted Citation Impact: 36.61